AstraZeneca (NYSE:AZN) – Analysts at Jefferies Group cut their FY2018 earnings estimates for shares of AstraZeneca in a research report issued on Friday, April 13th. Jefferies Group analyst I. Hilliker now expects that the company will post earnings of $1.67 per share for the year, down from their prior forecast of $1.70. Jefferies Group has a “Buy” rating and a $36.70 price objective on the stock.
Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Monday, April 9th. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a “buy” rating in a research report on Thursday, March 22nd. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Monday, March 19th. Leerink Swann raised their price objective on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a report on Tuesday, February 6th. Finally, Sanford C. Bernstein raised their price objective on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $38.12.
AstraZeneca stock opened at $35.86 on Monday. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. The firm has a market cap of $91,994.78, a price-to-earnings ratio of 8.38, a P/E/G ratio of 1.86 and a beta of 0.62. AstraZeneca has a fifty-two week low of $28.43 and a fifty-two week high of $36.75.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.21 earnings per share.
Several hedge funds have recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. acquired a new position in AstraZeneca in the fourth quarter valued at $101,000. Delpha Capital Management LLC acquired a new position in AstraZeneca in the fourth quarter valued at $152,000. Calton & Associates Inc. acquired a new position in AstraZeneca in the fourth quarter valued at $181,000. Green Square Capital LLC acquired a new position in AstraZeneca in the fourth quarter valued at $200,000. Finally, Neumann Capital Management LLC acquired a new position in AstraZeneca in the fourth quarter valued at $202,000. Institutional investors and hedge funds own 15.14% of the company’s stock.
The firm also recently disclosed a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were issued a dividend of $0.95 per share. This represents a dividend yield of 5.62%. The ex-dividend date was Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is 32.01%.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/18/astrazeneca-to-post-fy2018-earnings-of-1-67-per-share-jefferies-group-forecasts-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.